ASH25 Day 4: Don’t Miss The Highlights

The American Society of Hematology Congress 2025 (ASH25) is officially underway in Orlando, Florida, from December 6 to 9.

It aims to bring together hematology professionals from across the globe.

Throughout the meeting, experts will present new research, clinical breakthroughs, and innovations that are defining the future of hematologic care.

Find the highlights from Day 4

BIDMC Cancer Center:

”ASH25 highlight: A multidisciplinary look at thrombosis risk in Multiple Myeloma patients treated with carfilzomib-based regimens – a systematic review and meta-analysis of clinical trials: Prateek Pophali et al., Pedro Luiz L. B. Danielian, Rushad Patell

Read the full article here.

”

Sylvester Comprehensive Cancer Center:

”Our team presented impactful research at today’s ASH25 poster session.

Highlights included new insights across lymphoma, myeloma, acute myeloid leukemia, myelodysplastic syndromes, blastic plasmacytoid dendritic cell neoplasm and von Willebrand disease.

Learn more.

”

Yale Cancer Center:

”Deeksha Katoch reports longer driving distances to a hemophilia treatment center is linked to higher bleeding rates in people with inheritable bleeding disorders.

Next steps: studying long-term complications, bleeding markers and gender-based differences in care.

Read the full article here.

”

Laila Alkhouli:

”Presented my poster at ASH25 and humbled to receive the ASH Abstract Achievement Award!

What an unforgettable experience filled with science, inspiration, and incredible people!

Read the full article here.

”

Canan Dirican:

”Presented at ASH and grateful to receive an Abstract Achievement Award

Research that began as a question, now a conversation.

Appreciate the discussions and feedback!

Read the full article here.

”

Akshat Jain:

”What an inspiring week at ASH2025 — the American Society of Hematology annual meeting in Orlando!

Every year, this meeting reinforces why hematology is the beating heart of translational medicine.

A few key takeaways that deeply resonated:

Transformative Therapeutics: The science behind novel agents continues to redefine how we treat human disease.

The precision and creativity developed in blood disorders are now paving the way for breakthroughs across cancer, autoimmune, and metabolic diseases — a thrilling horizon for modern medicine.

Bench to Bedside in Action: Seeing how complex, chronic, and rare diseases are being approached with structured, risk-adapted protocols reminds me how rigor and compassion come together in true clinical innovation.

Industry: bouncing off ideas , laying Foundation for new collaborations and learning about pipeline always invigorate me.

Global Health Perspective: Hearing insights from colleagues across Europe, Asia, Africa, and beyond was humbling.

The diversity in strategy, resource utilization, and patient response reminds us that innovation thrives when we listen, learn, and adapt globally.

Community and Collaboration: The best part — reconnecting with mentors, peers, and new collaborators.

The exchange of ideas and the spark of potential partnerships always reignite my passion for research and patient care.

Grateful to be part of a field where discovery meets compassion every single day.

Thank you Andrea Fischer for keeping us informed and an amazing meeting.

”

Giulia Simini:

” What a week at ASH25!

Presenting my poster on AAV genome regulation sparked exciting discussions and ideas for the next stages of our research.

Grateful for the incredible mentorship and team support that brought this project to life.

Read the full article here.

”

Wolfgang Miesbach:

”Elevation of Liver Health Biomarkers Before and After Gene Therapy in Haemophilia B. Honored to share our phase 3 HOPE‑B trial data on liver parameters presented at ASH25

Our poster examined if and how ALT/AST elevations before or after gene therapy impact long‑term outcomes in people with haemophilia B treated with etranacogene dezaparvovec — an AAV5‑based vector delivering FIX‑Padua.

• Sustained FIX expression — participants maintained stable, clinically meaningful endogenous FIX activity after managing transaminase elevations with corticosteroids when needed
• Baseline liver abnormalities — individuals with 1–2× ULN ALT/AST at entry achieved comparable FIX levels and bleeding protection to those with normal baseline
• Individual trajectories matter — our data show not just aggregate responses but individual kinetics of FIX recovery and transaminase patterns, revealing heterogeneity in hepatic tolerance
• Robust bleeding control — annualized bleed rates (ABR) remained substantially reduced across all subgroups (including pre‑treatment and post‑treatment elevation cohorts)
• No hepatic deterioration — zero evidence of progressive liver disease over 4 years; rare transaminitis episodes resolved without sequelae

Etranacogene dezaparvovec demonstrates durable hepatic safety and FIX durability in haemophilia B, even in patients with mild baseline enzyme abnormalities, with appropriate surveillance and management

Grateful to patients, investigators, coordinators, and collaborators.

”

All from ASH25 featured in Hemostasis Today.